GMP and FDA reference library

FDA drug CGMP regulations overview. FDA introduces the manufacturing-quality regulations and identifies the relevant pharmaceutical rule categories. Start here when orienting a reader to the regulatory framework, then use the actual rule text to examine the requirement behind a task.

21 CFR 210: general drug CGMP. This part establishes the general framework and definitions for drug CGMP. Use it to understand scope and terminology before reading a more detailed operational provision, especially when familiar words such as batch and component need their regulatory meaning.

21 CFR 211: finished pharmaceuticals. The finished-pharmaceutical requirements cover personnel, facilities, equipment, materials, production, laboratory controls and records. Use the relevant provision when connecting an operational instruction with its regulatory basis, and read related sections together when the activity crosses departmental boundaries.

21 CFR 820: device QMSR. This is the Quality Management System Regulation for devices. Read its applicability and referenced requirements when considering device manufacturing controls; a pharmaceutical procedure or an older device discussion should not substitute for the relevant current framework.

21 CFR 111: dietary supplements. The dietary-supplement CGMP rule addresses manufacturing, packaging, labeling and holding operations. Use it for the supplement-specific requirements and scope conditions, rather than assuming that the finished-pharmaceutical framework applies unchanged to a supplement operation.

21 CFR 11: electronic records and signatures. This part describes criteria for electronic records and signatures to be considered trustworthy and reliable. Read the scope alongside the underlying record requirement when assessing an electronic workflow; using software alone does not settle which requirements apply.

21 CFR 1271: human cells and tissues. The rule addresses human cells, tissues and cellular and tissue-based products, including donor eligibility and current good tissue practice. Use its scope provisions and the relevant operational sections together, keeping tissue requirements distinct from general drug or device discussions.

What FDA regulates. FDA outlines the categories within its broad regulatory authority. Use this overview to orient a cross-functional discussion, then establish the specific product category and activity through the appropriate regulatory and company quality processes.

FDA QMSR overview. FDA explains the device framework and its incorporation of ISO 13485:2016. This page helps readers connect the terminology in Part 820 with the broader device quality-system discussion, while the rule remains the reference for the actual requirements.

Food and dietary-supplement CGMP overview. FDA outlines food CGMP subjects such as hygiene, facilities, equipment, sanitation and process controls, and identifies supplement-specific rules. Use it to distinguish the food and supplement frameworks before examining the applicable operational provisions.

FDA dietary-supplement overview. FDA describes its regulation of finished supplements and dietary ingredients and explains that their framework differs from conventional foods and drugs. Use it for sector context, alongside Part 111 when the question concerns manufacturing practice.

Process validation: general principles and practices. FDA identifies this guidance as addressing principles and approaches for validating drug manufacturing processes, including drug substances. Use the guidance for the validation subject and check its full scope before applying an approach to a particular process.

Quality-systems approach to pharmaceutical CGMP. FDA describes a quality-systems model consistent with drug CGMP and states that the guidance does not replace those requirements. Use it to connect management and system design with the operational rules, while continuing to consult the regulations.

ICH Q9(R1): quality risk management. FDA describes guidance on pharmaceutical quality-risk-management principles and tools, including concerns about subjectivity and clarity in decisions. It is a useful reference when discussing how a company makes an assessment understandable, reasoned and connected to process knowledge.

ICH Q10: pharmaceutical quality system. FDA identifies an internationally harmonised model for an effective pharmaceutical quality management system. Use it for the pharmaceutical quality-system subject, then connect the discussion with the company’s processes and the applicable CGMP requirements.

Data integrity and drug CGMP: questions and answers. FDA explains the guidance’s role in clarifying data integrity and its expectation of reliable, accurate data. Use it when reviewing risks in a record workflow, together with the underlying regulation and the company’s controlled documentation procedures.

Investigating out-of-specification results. FDA explains the scope of its guidance on results outside established specifications or acceptance criteria, including in-process laboratory tests. Use it to frame an OOS investigation question and connect the laboratory assessment with the wider production evidence.

Sterile products produced by aseptic processing. FDA identifies guidance intended to support CGMP requirements for sterile drug and biological manufacturing using aseptic processing. Use the subject-specific guidance when examining that setting, alongside the applicable rules and the company’s approved contamination-control procedures.

Investigations Operations Manual. FDA describes the manual as an operational reference for investigators and field employees, with inspection subjects among its contents. Use it to understand the agency’s operations when preparing people and records for an inspection discussion.

Form 483 questions and answers. FDA explains the purpose and implications of inspection observations, including that the document is not a final agency determination of a violation. Use it to understand the observation and response context before drawing conclusions from a Form 483.

Inspection observations. FDA explains its published observation summaries and their limitations, including that they do not include every observation. Use the summaries to identify questions for internal review, while avoiding conclusions that exceed the scope of the published data.

Warning letters. FDA publishes warning letters and cautions that later interaction may have changed an issue’s regulatory status. Use a letter to understand the issues described at that point and examine the available context before interpreting it as a statement of present conditions.

Recall background and definitions. FDA defines recalls and distinguishes their classifications from market withdrawals and device alerts. Use these definitions to clarify the terminology before discussing traceability, the scope of affected material or the manufacturing investigation connected with a recall.

WHO GMP overview. WHO explains GMP as part of quality assurance for consistent production and control against appropriate standards. The overview helps connect production and quality-control activities at a broad level; it does not replace the requirements applicable to a specific jurisdiction or operation.

European Commission: EudraLex Volume 4. The European Commission brings together references to legislation and guidance for interpreting medicinal-product GMP principles. Use its structure to locate the relevant European subject, keeping the applicable jurisdiction and product category clear when comparing it with a U.S. requirement.

PIC/S introduction. PIC/S describes a cooperative arrangement among regulatory authorities working on medicinal-product GMP and inspection harmonisation. Use the introduction to understand the body’s role and the purpose of common standards, rather than treating participation as a substitute for national regulatory requirements.

Write down the decision that needs support before reading. Identify the applicable sector and the activity, then examine the source’s scope and the relevant provision together. Keep regulatory requirements, agency explanations and general manufacturing reasoning distinct so that a practical suggestion does not become an unsupported statement about compliance.